Harnessing innate power: Targeting the root causes of inflammation and fibrosis
Our approach is to target upstream innate immune amplifiers that underpin persistent inflammatory and fibrotic responses to restore tissue homeostasis and disrupt disease progression.
Our journey
At Calluna Pharma we are developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential applicability across a diverse array of medical conditions. Calluna Pharma is a clinical stage company driven by a commitment to improve patient outcomes in areas where existing treatments are sub-optimal.
We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.
Our science
Leveraging over 30 years of research by our scientific co-founders, we have unlocked a groundbreaking therapeutic concept that allows us to tackle the root causes of inflammation and fibrosis.
Our unique approach involves precision targeting of upstream innate immune amplifiers, enabling us to disrupt a comprehensive range of disease-associated downstream signaling pathways while maintaining a favorable safety profile. Using these principles, we have developed a robust pipeline of first-in-class therapeutic antibodies that fulfil unmet clinical needs across a spectrum of diseases driven by acute or chronic inflammation and non-resolving tissue fibrosis.
Spearheading our portfolio is CAL101, a monoclonal antibody that neutralizes the bioactivity of S100A4. In chronically diseased tissue, S100A4’s inappropriate upregulation switches self-limiting tissue repair responses into chronic activation of inflammatory signaling pathways and sustained fibrogenesis. With CAL101, we aim to shift the paradigm, offering hope to patients grappling with serious and potentially life-threatening diseases such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, rheumatoid arthritis and severe (steroid insensitive) asthma.
Neutralizing upstream innate immune amplifiers provides a novel pleiotropic approach.
Interested in finding out more?
Therapeutic breakthroughs: Our pipeline
We have four promising therapies in the pipeline, with preclinical proof of concept data.
Keep up to date with our pipeline and company developments
Our team
We bring together a mix of skills and backgrounds, from various academic institutions to different roles in biotech and large pharma companies. Our collective experience helps us navigate the complexities of drug discovery and development, merging strategic thinking with practical know-how and a strong commitment to effective clinical execution.
Our C-suite executives
John Montana PhD
CEO
John’s 30 years of diverse R&D experience shapes Calluna Pharma’s innovative edge, blending drug discovery acumen with strong leadership.
Jonas Hallén MD PhD
CMO and Founder
As a co-founder and passionate drug developer, Jonas strongly believes in the power of science to make a meaningful impact on patients’ lives.
Louise Kooij
CFO
With a career spanning pharma and biotech, Louise provides Calluna Pharma with financial leadership, fostering strategic growth and stability.
Investors
Our unique therapeutic solutions, targeting sentinel modulators and key self-amplifying alarm signals of the immune system, present an exciting investment opportunity. Noted industry investor Forbion already recognizes Calluna Pharma’s potential and has made a strategic investment, underscoring our credibility and commercial promise.
A partnership with Calluna Pharma brings more than just the potential for financial gains. It’s an opportunity to contribute to improving patient outcomes and elevating therapeutic standards. The combination of our scientific excellence, discovery expertise, and accomplished management team, alongside our robust clinical plans could add considerable credibility to your investment portfolio.
Interested in transforming the therapeutic landscape for inflammatory and fibrotic diseases? Get in touch to find out more.
Latest News
Keep up to date with our recent breakthroughs and partnerships as we endeavour to identify novel life changing treatments for a range of inflammatory and fibrotic diseases.
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance
First senior executive appointment made following Company launch to oversee strategic development of clinical programs
Read more
Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases
Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx) announced their merger to form Calluna Pharma Inc.
Read more
More news coming soon
Get in touch
"*" indicates required fields